MY170326A - Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors - Google Patents

Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors

Info

Publication number
MY170326A
MY170326A MYPI2014003346A MYPI2014003346A MY170326A MY 170326 A MY170326 A MY 170326A MY PI2014003346 A MYPI2014003346 A MY PI2014003346A MY PI2014003346 A MYPI2014003346 A MY PI2014003346A MY 170326 A MY170326 A MY 170326A
Authority
MY
Malaysia
Prior art keywords
imidazo
pyridazine
derivativea
compound
kinase inhibitors
Prior art date
Application number
MYPI2014003346A
Other languages
English (en)
Inventor
Yuichi Tominaga
Ryoichi Tanaka
Yuko Yamamoto
Kenji Yoshikawa
Yasuyuki Takeda
Yoshiko Kagoshima
Masaki Kiga
Yoshito Hamada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MY170326A publication Critical patent/MY170326A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2014003346A 2012-06-04 2013-06-03 Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors MY170326A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04

Publications (1)

Publication Number Publication Date
MY170326A true MY170326A (en) 2019-07-17

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014003346A MY170326A (en) 2012-06-04 2013-06-03 Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors

Country Status (32)

Country Link
US (2) US9187489B2 (OSRAM)
EP (1) EP2857404B1 (OSRAM)
JP (1) JP5814467B2 (OSRAM)
KR (1) KR101781255B1 (OSRAM)
CN (1) CN104520300B (OSRAM)
AU (1) AU2013272701B2 (OSRAM)
BR (1) BR112014029851B1 (OSRAM)
CA (1) CA2874819C (OSRAM)
CO (1) CO7160119A2 (OSRAM)
CY (1) CY1119607T1 (OSRAM)
DK (1) DK2857404T3 (OSRAM)
ES (1) ES2648228T3 (OSRAM)
HR (1) HRP20171724T1 (OSRAM)
HU (1) HUE037221T2 (OSRAM)
IL (1) IL236075A (OSRAM)
IN (1) IN2014MN02497A (OSRAM)
LT (1) LT2857404T (OSRAM)
MX (1) MX357021B (OSRAM)
MY (1) MY170326A (OSRAM)
NO (1) NO2857404T3 (OSRAM)
NZ (1) NZ702574A (OSRAM)
PH (1) PH12014502721A1 (OSRAM)
PL (1) PL2857404T3 (OSRAM)
PT (1) PT2857404T (OSRAM)
RS (1) RS56625B1 (OSRAM)
RU (1) RU2635917C2 (OSRAM)
SG (1) SG11201408052WA (OSRAM)
SI (1) SI2857404T1 (OSRAM)
SM (1) SMT201700539T1 (OSRAM)
TW (1) TWI585088B (OSRAM)
WO (1) WO2013183578A1 (OSRAM)
ZA (1) ZA201408843B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
PT3372605T (pt) 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SMT201900203T1 (it) 2010-05-20 2019-05-10 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
ES2715676T3 (es) 2014-03-27 2019-06-05 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inhibidores de ros1
WO2015144801A1 (en) * 2014-03-27 2015-10-01 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
AR100191A1 (es) * 2014-04-25 2016-09-14 Exelixis Inc Método para tratar adenocarcinoma de pulmón
CA2967951C (en) 2014-11-16 2023-11-07 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR20180021745A (ko) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 암을 진단하고 치료하는 방법
EP3310441B1 (en) 2015-06-18 2020-07-29 89Bio Ltd. 1, 4-substituted piperidine derivatives
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換4−ベンジル及び4−ベンゾイルピペリジン誘導体
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
PH12018502124B1 (en) 2016-04-04 2024-04-12 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JP7057343B2 (ja) 2016-04-04 2022-04-19 ロクソ オンコロジー, インコーポレイテッド 小児癌の処置方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PT3458456T (pt) 2016-05-18 2020-12-07 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JP7082608B2 (ja) * 2017-03-14 2022-06-08 第一三共株式会社 3,6-ジ置換イミダゾ[1,2-b]ピリダジン誘導体の製造方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
JP7174143B2 (ja) 2018-07-24 2022-11-17 大鵬薬品工業株式会社 Shp2活性を阻害するヘテロ二環性化合物
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
TW202100526A (zh) 2019-03-06 2021-01-01 日商第一三共股份有限公司 吡咯并吡唑衍生物
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
MX2021013576A (es) * 2019-05-08 2021-12-15 Tyk Medicines Inc Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
US20240309007A1 (en) * 2021-07-01 2024-09-19 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
KR20250056969A (ko) 2022-09-07 2025-04-28 수저우 랑루이 바이오파마슈티컬 씨오 엘티디 마크로시클릭 이미다조[1,2-b]피리다진 유도체 및 이의 제조 방법과 용도
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
JP2004508366A (ja) 2000-09-01 2004-03-18 グラクソ グループ リミテッド オキシインドール誘導体
EP1339680A1 (en) 2000-09-01 2003-09-03 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
EP1832588A4 (en) * 2004-12-28 2009-09-02 Takeda Pharmaceutical CONDENSED IMIDAZOLE COMPOUND AND ITS USE
ES2555063T3 (es) 2005-02-04 2015-12-28 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
ATE473975T1 (de) 2005-02-16 2010-07-15 Astrazeneca Ab Chemische verbindungen
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Lck阻害剤としての縮合複素環
WO2007014707A1 (en) * 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
AU2009246687B2 (en) * 2008-05-13 2012-08-09 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2952692C (en) * 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
RU2635917C2 (ru) 2017-11-17
ES2648228T3 (es) 2017-12-29
US9187489B2 (en) 2015-11-17
CY1119607T1 (el) 2018-04-04
EP2857404A4 (en) 2016-01-20
MX2014014803A (es) 2015-02-12
SG11201408052WA (en) 2015-01-29
MX357021B (es) 2018-06-25
RS56625B1 (sr) 2018-03-30
US20150051190A1 (en) 2015-02-19
LT2857404T (lt) 2017-11-10
HRP20171724T1 (hr) 2018-01-12
ZA201408843B (en) 2016-01-27
PH12014502721B1 (en) 2015-02-02
JPWO2013183578A1 (ja) 2016-01-28
US9751887B2 (en) 2017-09-05
KR101781255B1 (ko) 2017-09-22
DK2857404T3 (en) 2017-12-04
EP2857404B1 (en) 2017-08-23
AU2013272701B2 (en) 2017-12-21
IN2014MN02497A (OSRAM) 2015-07-17
WO2013183578A1 (ja) 2013-12-12
PT2857404T (pt) 2017-11-23
PL2857404T3 (pl) 2018-04-30
TW201400486A (zh) 2014-01-01
BR112014029851B1 (pt) 2023-01-03
TWI585088B (zh) 2017-06-01
PH12014502721A1 (en) 2015-02-02
NO2857404T3 (OSRAM) 2018-01-20
KR20150014942A (ko) 2015-02-09
CO7160119A2 (es) 2015-01-15
SI2857404T1 (sl) 2017-11-30
RU2014153627A (ru) 2016-08-10
BR112014029851A2 (pt) 2017-06-27
CA2874819A1 (en) 2013-12-12
IL236075A0 (en) 2015-02-01
US20160046639A1 (en) 2016-02-18
NZ702574A (en) 2016-07-29
IL236075A (en) 2017-10-31
AU2013272701A2 (en) 2015-01-22
CN104520300A (zh) 2015-04-15
EP2857404A1 (en) 2015-04-08
HUE037221T2 (hu) 2018-08-28
CA2874819C (en) 2017-06-20
HK1207374A1 (en) 2016-01-29
CN104520300B (zh) 2016-12-21
AU2013272701A1 (en) 2015-01-15
SMT201700539T1 (it) 2018-01-11
JP5814467B2 (ja) 2015-11-17

Similar Documents

Publication Publication Date Title
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
GEP20156285B (en) Compounds and compositions as trk inhibitors
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
PH12014500137A1 (en) Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
MY172924A (en) Neprilysin inhibitors
PH12013501750A1 (en) Guanidine compound
BR112012019765A2 (pt) composto, e, uso de um composto.
MX354476B (es) Inhibidores de neprilisina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2011127406A3 (en) Acridines as inhibitors of haspin and dyrk kinases
IN2014MN02433A (OSRAM)
TR201901937T4 (tr) 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri.